Wire · opportunities
Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License's Sentivera ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
Biohaven granted SK Biopharmaceuticals an exclusive worldwide license to its Kv7 ion channel platform, including opakalim for epilepsy, with upfront and milestone payments potentially reaching $795 million. Separately, Haisco licensed a preclinical type 2 inflammatory disease asset to Sentivera via a Newco partnership valued over $1.5 billion.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can access late-stage biotech assets via licensing partnerships and Newco structures that bring significant upfront capital without needing your own commercial setup. This strategy opens pathways to accelerate development and global reach while preserving financial upside.
◆ Coverage
1 source · 26 Aug 2026
◆ Related on Wire
◆ Topics